Publications (18) MIRIAM LÓPEZ PARRA publications

2024

  1. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma

    Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data

    Journal of Personalized Medicine, Vol. 14, Núm. 5

  4. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy, Vol. 26, Núm. 8, pp. 806-812

2023

  1. Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial

    Stem cell research & therapy, Vol. 14, Núm. 1, pp. 78

  2. Autologous mesenchymal stromal cells embedded with Tissucol Duo® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up

    Stem Cell Research and Therapy, Vol. 14, Núm. 1

  3. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

  4. Long-Term Results of a Phase I/II Clinical Trial of Autologous Mesenchymal Stem Cell Therapy for Femoral Head Osteonecrosis

    Journal of Clinical Medicine, Vol. 12, Núm. 6

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  2. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

2021

  1. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH)

    Transfusion and Apheresis Science, Vol. 60, Núm. 2

  2. Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients

    PLoS ONE, Vol. 16, Núm. 4 April

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

2019

  1. Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: Results of a prospective phase I/II clinical trial with long-term follow-up

    Stem Cell Research and Therapy, Vol. 10, Núm. 1

  2. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2015

  1. A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation

    Clinical Microbiology and Infection

  2. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834